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A B S T R A C T
Introduction. In 2009, the International Society for Sexual Medicine (ISSM) convened a select panel of experts to
develop an evidence-based set of guidelines for patients suffering from lifelong premature ejaculation (PE). That
document reviewed deﬁnitions, etiology, impact on the patient and partner, assessment, and pharmacological,
psychological, and combined treatments. It concluded by recognizing the continually evolving nature of clinical
research and recommended a subsequent guideline review and revision every fourth year. Consistent with that
recommendation, the ISSM organized a second multidisciplinary panel of experts in April 2013, which met for 2 days
in Bangalore, India. Thismanuscript updates the previous guidelines and reports on the recommendations of the panel
of experts.
Aim. The aim of this study was to develop clearly worded, practical, evidenced-based recommendations for the
diagnosis and treatment of PE for family practice clinicians as well as sexual medicine experts.
Method. A comprehensive literature review was performed.
Results. This article contains the report of the second ISSM PE Guidelines Committee. It offers a new uniﬁed
deﬁnition of PE and updates the previous treatment recommendations. Brief assessment procedures are delineated,
and validated diagnostic and treatment questionnaires are reviewed. Finally, the best practices treatment recommen-
dations are presented to guide clinicians, both familiar and unfamiliar with PE, in facilitating treatment of their
patients.
Conclusion. Development of guidelines is an evolutionary process that continually reviews data and incorporates the
best new research. We expect that ongoing research will lead to a more complete understanding of the
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pathophysiology as well as new efﬁcacious and safe treatments for this sexual dysfunction. We again recommend that
these guidelines be reevaluated and updated by the ISSM in 4 years. Althof SE, McMahon CG, Waldinger MD,
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Introduction
I n 2009, the International Society for SexualMedicine (ISSM) convened a select panel of
experts to develop an evidence-based set of guide-
lines for patients suffering from lifelong premature
ejaculation (LPE) [1]. That document reviewed
deﬁnitions, etiology, impact on the patient and
partner, assessment, and pharmacological, psycho-
logical, and combined treatments. It concluded by
recognizing the continually evolving nature of
clinical research and recommended a subsequent
guideline review and revision every fourth year.
Consistent with that recommendation, the
ISSM organized a second multidisciplinary panel
of experts in April 2013, which met for 2 days in
Bangalore, India. The committee members were
selected to assure diversity of discipline, balance of
opinion, knowledge, gender, and geography.
Twenty members consisting of nine urologists,
three psychiatrists, three psychologists, one family
practice physician, one endocrinologist, one sexual
medicine physician, one radiation oncologist, and
one pharmacologist comprised the group. The
committee was chaired by Chris McMahon, MD.
Prior to the meeting, the committee members
received a comprehensive literature review and
were asked to critically assess the previous guide-
lines. Members were assigned speciﬁc topic for
presentation, and a writing committee was chosen
to craft this document. Quality of evidence and the
strength of recommendation were graded using the
Oxford Centre of Evidence-Based Medicine
system [2].
The meeting was supported by an unrestricted
grant from Johnson & Johnson (New Brunswick,
NJ, USA), the manufacturer of dapoxetine. ISSM
required complete independence from industry;
there were no industry representatives at the
meeting and there was no attempt by industry to
inﬂuence the writing process at any time [3].
Members were required to declare in advance any
conﬂicts of interests.
Definitions of Premature Ejaculation (PE)
Several deﬁnitions forPEexist, having beendrafted
by various professional organizations or profes-
sionals [4–11] (see Table 1), and most include the
PE subtypes of lifelong and acquired (PE symp-
toms beginning after a period of normal ejaculatory
function). The major criticisms of the extant deﬁ-
nitions included their failure to be evidence based,
lack of speciﬁc operational criteria, excessive
vagueness, and reliance on the subjective judgment
of the diagnostician [12]. Nonetheless, three
common constructs underlie most deﬁnitions of
PE: (i) a short ejaculatory latency; (ii) a perceived
lack of control or inability to delay ejaculation, both
related to the broader construct of perceived self-
efﬁcacy; and (iii) distress and interpersonal difﬁ-
culty to the individual and/or partner (related to the
ejaculatory dysfunction) [12].
Because of the discontent with the existing PE
deﬁnitions, as well as pressure from regulatory
agencies concerning the inadequacy of the deﬁni-
tions, the ISSM convened in 2007 and again in
2013, a meeting of experts to develop a deﬁnition
grounded in clearly deﬁnable scientiﬁc criteria
[12]. After carefully reviewing the literature, the
committee proposed a uniﬁed deﬁnition of both
LPE and acquired PE (APE): It “is a male sexual
dysfunction characterized by:
• ejaculation that always or nearly always occurs
prior to or within about 1 minute of vaginal pen-
etration from the ﬁrst sexual experience (LPE),
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OR a clinically signiﬁcant reduction in latency
time, often to about 3 minutes or less (acquired
premature ejaculation);
• the inability to delay ejaculation on all or nearly
all vaginal penetrations; and
• negative personal consequences, such as dis-
tress, bother, frustration, and/or the avoidance
of sexual intimacy.” Level of evidence (LOE 1a)
The deﬁnition applies to both LPE and APE but
is limited to intravaginal sexual activity, as correla-
tions between coital, oral sex, and masturbatory
latencies are not consistently high. In addition, it
does not deﬁne PE when men have sex with men.
The committee concluded that there was insufﬁ-
cient information available to extend the deﬁnition
to these other situations or groups. (LOE 5d)
The Diagnostic and Statistical Manual of
Mental Disorders, Fifth Edition (DSM-5) [13]
deﬁnition of premature (early) ejaculation, pub-
lished in 2013, is consistent with the ISSM deﬁni-
tion and includes the approximately 1-minute
intravaginal ejaculatory latency time (IELT) crite-
ria as well as the inclusion of distress. It also asks
the clinician to specify the subtypes of lifelong and
acquired, generalized, or situational as well as the
severity of the dysfunction.
Anteportal ejaculation is the term applied to
men who ejaculate prior to vaginal penetration and
is considered the most severe form of PE. Such
men or couples typically present when they are
having difﬁculty conceiving children. It is esti-
mated that between 5% and 20% of men with
LPE suffer from anteportal PE [14].
The committee recognized that some men who
self-diagnose PE and present for treatment fail to
fulﬁll the ISSM criteria for PE. Waldinger has
proposed two additional “subtypes” of men who
Table 1 Definitions of premature ejaculation established through consensus committees and/or professional
organizations
Definition Source
A male sexual dysfunction characterized by ejaculation that always or nearly always occurs prior to
or within 1 minute of vaginal penetration, either present from the first sexual experience or
following a new bothersome change in ejaculatory latency, and the inability to delay ejaculation
on all or nearly all vaginal penetrations, and negative personal consequences, such as distress,
bother, frustration, and/or the avoidance of sexual intimacy.
International Society of Sexual
Medicine, 2013
A. Persistent or recurrent pattern of ejaculation occurring during partnered sexual activity within
approximately 1 minute following vaginal penetration and before the individual wishes it (Note:
Although the diagnosis of premature [early] ejaculation may be applied to individuals engaged in
non-vaginal sexual activities, specific duration criteria have not been established for these
activities).
B. The symptom in Criterion A must have been present for at least 6 months and must be
experienced on almost all or all ( approximately 75%–100%) occasions of sexual activity (in
identified situational contexts or, if generalized, in all contexts).
C. The symptom in Criteria A causes clinically significant distress in the individual.
D. The sexual dysfunction is not better explained by a nonsexual mental disorder or as a
consequence of severe relationship distress or other significant stressors and is not attributable
to the effects of a substance/medication or another medical disorder.
DSM-5, 2013
Persistent or recurrent ejaculation with minimal sexual stimulation, before, on or shortly after
penetration and before the person wishes it. The condition must also cause marked distress or
interpersonal difficulty and cannot be due exclusively to the direct effects of a substance.
DSM-IV-TR, 2000
For individuals who meet the general criteria for sexual dysfunction, the inability to control
ejaculation sufficiently for both partners to enjoy sexual interaction, manifest as either the
occurrence of ejaculation before or very soon after the beginning of intercourse (if a time limit is
required, before or within 15 seconds) or the occurrence of ejaculation in the absence of
sufficient erection to make intercourse possible. The problem is not the result of prolonged
absence from sexual activity.
International Statistical
Classification of Disease, 10th
Edition, 1994
The inability to control ejaculation for a “sufficient” length of time before vaginal penetration. It does
not involve any impairment of fertility, when intravaginal ejaculation occurs.
European Association of Urology.
Guidelines on Disorders of
Ejaculation, 2001
Persistent or recurrent ejaculation with minimal stimulation before, on, or shortly after penetration,
and before the person wishes it, over which the sufferer has little or no voluntary control, which
causes the sufferer and/or his partner bother or distress.
International Consultation on
Urological Diseases, 2004
Ejaculation that occurs sooner than desired, either before or shortly after penetration, causing
distress to either one or both partners.
American Urological Association
Guideline on the Pharmacologic
Management of Premature
Ejaculation, 2004
DSM-5 definition reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (Copyright ©2013). American Psychiatric
Association. All Rights Reserved.
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are distressed about their ejaculatory function but
do not meet the diagnostic criterion for PE. He
designated them as variable PE (VPE) and subjec-
tive PE (SPE) [10,15]. These subtypes should be
considered provisional; however, we believe these
categories may help health care professionals
(HCPs) address the concerns of men who do not
qualify for the diagnosis of PE but are seeking
help. VPE is characterized by short ejaculatory
latency that occurs irregularly and inconsistently
with some subjective sense of diminished control
of ejaculation. This subtype is not considered a
sexual dysfunction but rather a normal variation in
sexual performance. SPE is characterized by one
or more of the following: (i) subjective perception
of consistent or inconsistent short IELT; (ii) pre-
occupation with an imagined short ejaculatory
latency or lack of control over the timing of ejacu-
lation; (iii) actual IELT in the normal range or
even of longer duration (i.e., an ejaculation that
occurs after 5 minutes); (iv) ability to control
ejaculation (i.e., to withhold ejaculation at the
moment of imminent ejaculation) that may be
diminished or lacking; and (v) the preoccupation
that is not better accounted for by another mental
disorder. (LOE 5d)
Epidemiology
PE has been recognized as a syndrome for well
over 100 years [16]. Despite this long history, the
prevalence of the condition remains unclear. This
ambiguity derives in large part from the difﬁculty
deﬁning what constitutes clinically relevant PE.
Vague deﬁnitions without speciﬁc operational
criteria, different modes of sampling, and
nonstandardized data acquisition have led to tre-
mendous variability in estimated prevalence
[1,12,17–19]. The sensitive nature of PE further
hampers the reliability of epidemiologic studies;
the small fraction of the male population willing
to answer questions concerning their sexual lives
may not be representative of the larger popula-
tion of men [20,21]. In addition, some men with
genuinely rapid ejaculation times may be reluc-
tant to report this complaint due to worry about
social stigmatization [22]. Conversely, healthy
individuals may report PE because of the incen-
tives provided by researchers, the belief that they
will beneﬁt from participation in a survey [22], or
a misunderstanding of what is typical with
respect to ejaculatory latency in real-world sexual
encounters [8]. Aside from difﬁculties with deﬁ-
nitions and sampling, there is marked variability
in distress related to early ejaculation between
individual men and across cultures [8]. It is likely
that some men may report early ejaculation when
asked a single-item question on an epidemiologi-
cal survey while not experiencing bother sufﬁ-
cient to justify medical attention. Based on the
absence of distress, such men would not meet the
current criteria for PE [12,23].
Peer-reviewed studies on the prevalence of PE
published prior to March 2013 are summarized in
Table 2 [26,27,29,30,33–35,37–41,43–46,48–59].
Most of these studies utilized the DSM, Fourth
Edition, Text Revision (IV-TR) deﬁnition and
characterized PE as the “most commonmale sexual
dysfunction,” with a prevalence rate of 20–30%
[20–22]. As the DSM-IV-TR deﬁnition lacks
objective diagnostic criteria, the high prevalence of
PE reported in many of these surveys is a source
of ongoing debate [30,33,40,46,53,55,58,59]. It is,
however, unlikely that the PE prevalence is as
high as 20–30% based on the relatively low
number of men who present for treatment of PE
[21,54,57].
In two online surveys, one of Arabic-speaking
men in the Middle East, the second of US men,
82.6% and 78% of participants, respectively,
reported some degree of PE [43,49]. This high rate
of PE is best accounted for by the inclusion of men
with VPE or SPE. In the Middle Eastern study,
only 15.3% of men reported that they “always”
ejaculated before they wished, while 46% and 21%
described themselves, respectively, as “sometimes”
or “mostly” ejaculating before they wished. In the
US study, the 78% of men acknowledging some
degree of PE decreased to 14.4% when combining
the “always’ or “mostly” group.
In two ﬁve-nation (Turkey, United States,
United Kingdom, the Netherlands, and Spain)
studies of IELT in men from the general popu-
lation, the median IELT was 5.4 minutes (range
0.55–44.1 minutes) and 6.0 minutes (range 0.1–
52.7 minutes), respectively [8,56]. In these
samples, 2.5% of men had an IELT of less than 1
minute and 6% of less than 2 minutes PE
[1,8,56]. These percentages are not necessarily
equivalent to the prevalence of LPE because
there was no assessment of distress or chronicity
[8,56].
Based on these data and the ISSM and DSM-5
deﬁnition of PE, in terms of an IELT of about 1
minute, the prevalence of LPE is unlikely to
exceed 4% of the general population. (LOE 3b)
Serefoglu et al. were the ﬁrst to report preva-
lence rates for the four PE subtypes [40,58,59] as
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described by Waldinger and Schweitzer [10,15,23]
A 2010 study reported the distribution of PE
subtypes in PE patients admitted to a urology out-
patient clinic in Turkey, while a subsequent 2011
study reported the prevalence of PE subtypes in the
general male population in Turkey randomly
selected by a proportional sampling method
according to postal code [40,58]. This research
design was replicated by Zhang et al. [53] and Gao
et al. [50] in a Chinese population. In both these
studies, a relatively high proportion of men (20.0%
in Turkey and 25.8% in China) acknowledged a
concern with ejaculating too quickly, consistent
with previously reported prevalence studies of PE
[21]. Employing Waldinger’s deﬁnition [10,23], in
the general male population of both countries, the
prevalence of LPE was 2.3% and 3%, whereas the
prevalence ofAPEwas 3.9%and4.8%, respectively
[40,50]. The prevalence of VPE and SPEwas 8.5%
and 5.1% in Turkey and 11% and 7% in China,
respectively [40,50].
An approximately 5% prevalence of APE and
LPE in general populations is consistent with epi-
demiological data indicating that around 5% of the
population have an ejaculation latency less than 2
minutes. (LOE 3b)
There are signiﬁcant differences between PE
prevalence rates in the general population and
clinic settings because the majority of men with
PE do not seek treatment. Of patients presenting
for treatment, 36% to 63% have LPE and 16%
to 28% have APE [53,58]. The prevalence of
VPE and SPE among these clinic patients
was 14.5% and 6.9% in the Turkish clinic and
12.7% and 23.5% in the Chinese clinic patients
[53,58].
Etiology
Early PE investigators did not often differentiate
between APE and LPE, nor were there objective
criteria for what constituted PE in general [4,6].
With the development of the ISSM deﬁnition
[12] and two new PE syndromes VPE and SPE
[15,57], it is increasingly important to clarify
which syndrome is being addressed in etiological
studies.
Historical ambiguity on what constitutes early
ejaculation has led to a diverse list of potential and
established etiological factors [1]. Classically, PE
was thought to be psychologically or interperson-
ally based, due in large part to anxiety or condi-
tioning toward rapid ejaculation based on rushed
early sexual experiences [6,60]. Over the past two
decades, somatic and neurobiological etiologies
for early ejaculation have been hypothesized.
Myriad biological factors have been proposed to
explain PE including: hypersensitivity of the glans
penis [61], robust cortical representation of the
pudendal nerve [62], disturbances in central
serotonergic neurotransmission [63,64], erectile
difﬁculties and other sexual comorbidities [65,66],
prostatitis [67], detoxiﬁcation from prescribed
medications [68,69], recreational drugs [70],
chronic pelvic pain syndrome (CPPS) [71], and
thyroid disorders [72,73]. It is noteworthy that
none of these etiologies has been conﬁrmed in
large scale studies.
Neurobiology of PE
Serotonin is the neurotransmitter of greatest inter-
est in the control of ejaculation and has the most
robust data in animal and human models.
Waldinger hypothesized that lifelong early ejacu-
lation in humans may be explained by a
hyposensitivity of the 5-HT2C and/or hypersen-
sitivity of the 5-HT1A receptors [19]. As serotonin
tends to delay ejaculation, men low in 5-HT
neurotransmission and/or 5-HT2C receptor
hyposensitivity may have intrinsically lower ejacu-
latory thresholds. (LOE 3b)
Serotonin dysregulation as an etiological
hypothesis for LPE has been postulated to explain
only a small percentage (2–5%) of complaints of
PE in the general population [74]. (LOE 2a)
Dopamine and oxytocin also appear to play
important roles in ejaculation; the biology of these
neurotransmitters in relation to ejaculation is less
well studied, but in animal studies, both appear to
have a stimulatory effect on ejaculation [75,76].
(LOE 3b)
In the spinal cord, lumbar spinothalamic
neurons have been implicated as essential to the
ejaculatory reﬂex in rats [77–80] constituting a
spinal generator of ejaculation [81] (LOE2a).
There is also preliminary evidence that such a
neural organization also exists in humans [82]. The
relevance of these ﬁndings to PE is not yet appar-
ent, but this remains a fertile area for further trans-
lational research.
Genetics of PE
Genetic variations have been proposed to bring
about differences in the neurobiological factors
associated with PE. A genetic cause for PE was
ﬁrst hypothesized in 1943 based on family preva-
lence studies [60]. Waldinger et al. conﬁrmed this
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ﬁnding by surveying family members of 14 men
with a lifelong IELT less than 1 minute. Data on
ejaculation latency in these male relatives were
obtained by interview (n = 11) or “family history”
(n = 6). Lifelong IELT of less than 1 minute was
found in 88% of these ﬁrst-degree male relatives
of men with LPE [83].
In 2007, Jern et al. reported on genetic and
environmental risk factors for ejaculation distur-
bances in 1,196 Finnish twins [84]. Modeling of
etiological factors for early ejaculation (based on a
subjective symptom scale) suggested a moderate
additive genetic inﬂuence on propensity toward
early ejaculation; however, a large portion of the
variance in the frequency of early ejaculation was
related to non-shared environmental variance,
suggesting that genetic inﬂuences may create a
diathesis or predisposition to PE rather than a
direct cause-and-effect relationship [84].
The ﬁrst DNA-based study on PE was per-
formed by Janssen et al. in 89 Dutch men with
LPE (conﬁrmed by stopwatch IELT) compared
with a cohort of mentally and physically healthy
Dutch Caucasian men [85]. The target of this
assessment was a gene polymorphism for the
serotonin transporter protein (5-HTTLPR). This
polymorphism has long (L) and short (S) allelic
variants; the L alleles lead to greater transcrip-
tional activity and hence decreased synaptic sero-
tonin. In the LPE group, men homozygous for
the L allele had ejaculation latencies that were
half as long as men with the SL or SS genotypes.
Given that the L allele leads to reduced synaptic
serotonin, this ﬁnding is consistent with our
current understanding of the inﬂuence of sero-
tonin on ejaculation latency [85]. However, there
was no difference in the prevalence of the LL, SL,
and SS genotypes in men with LPE compared
with their prevalence in the general male Dutch
population, which suggests that this polymor-
phism alone cannot account for PE [85].
Follow-up studies on this same gene locus from
other investigators have been mixed, with one
report [86] being consistent with Janssen et al.’s
ﬁndings, another reporting no association
between 5-HTTLPR allele type and early ejacu-
lation [87], and another study ﬁnding the exact
opposite relationship between ejaculation latency
and L vs. S allele carries [88].
A new body of research on tandem repeats of
the dopamine transporter gene (DAT-1) as a
modulator of ejaculation latency has emerged [89–
91]. Men with longer tandem repeat lengths have
greater transcription of the transporter and hence,
less synaptic dopamine activity [89]. Santtila et al.
reported that men with longer tandem repeats
were more likely to endorse symptoms consistent
with early ejaculation [89]. A few studies, mainly
performed in general male twin studies, have
investigated polymorphism receptors for sero-
tonin, oxytocin, and/or vasopressin [92]. Prelimi-
nary ﬁndings have not indicated a marked
preponderance of any one genetic polymorphism
in men with symptoms of early ejaculation
[92–94].
The current body of evidence suggests that
individual genetic polymorphisms exert a minor, if
any, effect on ejaculation latency. Men with
numerous genetic variants may be predisposed to
development of PE, but data remain scant and
controversial. (LOE 2a)
Special Patient Populations
Thyroid Hormones
Data from animal studies suggest anatomic and
physiologic interactions between brain dopamine
and serotonin systems and the hypothalamic-
pituitary thyroid axis [95–97]. Corona et al. and
Carani et al. reported a signiﬁcant correlation
between APE and suppressed thyroid-stimulating
hormone and high thyroid hormone values in
andrological and sexological patients [72,73].
After normalizing thyroid function in hyperthy-
roid men, the prevalence of APE fell from 50%
to 15% [72]. These data have been conﬁrmed in
several other reports [72,98–101]. However, no
link has been found between thyroid hormones
and PE in a large cohort of men with LPE
[102].
Hyperthyroidism (an acquired condition) has
no role in LPE and has been found to be associated
with APE in extremely few patients [103]. (LOE
2a)
Other Hormones
Although it is well established that male reproduc-
tion and sexuality are hormonally regulated, the
endocrine control of the ejaculatory reﬂex is still
not completely clariﬁed. Recent studies on large
populations indicate that the endocrine system is
involved in the control of ejaculatory function and
that prolactin (PRL) and testosterone play inde-
pendent roles [100]. In particular, in a consecutive
series of 2,531 outpatients consulting for sexual
dysfunctions, PRL in the lowest quartile levels is
associated with APE and anxiety symptoms [104].
Additionally, higher testosterone levels correlate
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with PE, while lower androgenization is related to
delayed ejaculation [105].
Both hypoprolactinemia and relatively high
testosterone levels cannot be considered etiolo-
gies of APE. The relationship between these
hormonal abnormalities and PE is unclear.
(LOE 2a)
Prostatitis
Twenty-six to 77% of men with chronic prosta-
titis (CP) or CPPS report early ejaculation
[71,106,107]. Prostatic inﬂammation and chro-
nic bacterial prostatitis have been reported as
common ﬁndings in men with APE [67,108]. Con-
sidering the role of the prostate in the ejaculatory
mechanism, a direct inﬂuence of the local inﬂam-
mation in the pathogenesis of a few cases of APE
seems possible [109].
The mechanism linking CP and PE is unknown,
and there are some methodological limitations of
the existing data.While physical andmicrobiologi-
cal examination of the prostate expression in men
with painful ejaculation or CP/CPPS is recom-
mended, there is insufﬁcient evidence to support
routine screening of men with PE for this condi-
tion. (LOE 3a)
Erectile Dysfunction
Patients may mislabel or confuse the syndromes
of PE and erectile dysfunction (ED). Examples
include patients who say they have ED because
they are unable to rapidly achieve a second erec-
tion after ejaculation. Similarly, some men with
ED may self-report having PE because they rush
intercourse to prevent loss of their erection and
consequently ejaculate rapidly. This may be com-
pounded by the presence of high levels of perfor-
mance anxiety related to their ED, which serves to
worsen their prematurity.
PE and ED may be comorbid conditions in
some men [66]. In a global study of 11,205 men
from 29 countries, Laumann et al. reported that a
history of “sometimes” or “frequently” experienc-
ing difﬁculty attaining and maintaining erections
was independently predictive of “sometimes” or
“frequently” experiencing early ejaculation within
the past year. This relationship occurred across all
regions, with odds ratios ranging from 3.7 to 11.9
[20]. Smaller studies from general and clinic
populations have also reported this association
between self-reported PE and self-reported ED
[31,35,43,45,110–112], as determined by ED and
PE patient-reported outcomes (PROs) [41,45,48].
Conversely, some population studies have not
detected an association between ED and PE
[30,32,44,46,113].
In an integrated analysis of two double-blind
placebo controlled trials of dapoxetine for PE
(DSM criteria and IELT < 2 minutes), the preva-
lence of ED was higher in men with APE vs.
LPE (24% vs. 15%) [114]. Men with mild ED
had less control over ejaculation compared with
men with no ED and LPE [114]. This relation-
ship was most pronounced in men with LPE and
mild ED.
Comorbid ED is associated with more severe
PE symptoms. In a stopwatch study of 78 men
with LPE, McMahon reported that men with a
normal Sexual Health Inventory for Men (SHIM,
a metric for assessment of ED risk) had a signiﬁ-
cantly greater geometric mean IELT compared
with men with an abnormal SHIM suggestive of
ED (18 seconds vs. 11 seconds, respectively)
[115].
As in so many other areas of PE research, inter-
pretation of data on the association between ED
and PE is limited by varied deﬁnitions of PE and
the means employed to assess PE.
While ED is unlikely as a comorbidity or etio-
logical factor for LPE, there are data to support
that APE is associated with ED [114,116–119]
(LOE 3b). In such cases, men may experience rapid
ejaculation due to performance anxiety, or due to
deliberate intensiﬁcation of stimulation so as to
complete ejaculation before loss of tumescence
(LOE 5).
Men with comorbid ED and PE may manifest a
more severe variant of each disorder; furthermore,
such men may experience lower sexual satisfaction
and diminished response to treatment of PE [114].
(LOE 2a)
PE in Men Who Have Sex with Men. Data on the
prevalence of PE in men who have sex with men
(MSM) are relatively sparse. Existing studies
suggest that a substantial proportion of MSM
report PE and associated sexual bother. In some
cases, ejaculatory dysfunction in MSM has been
associated with higher risk of sexual behavior
and/or social recrimination [120]. Most contem-
porary studies suggest a similar prevalence of
concern about early ejaculation in MSM when
compared with men who have sex with women
only (MSW) [44]. Some older studies have sug-
gested that the rate of distressing ejaculation prob-
lems in MSM is lower than in MSW [121].
However, differences in relationships and sexual
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activities may be responsible for some of these
purported differences [122].
There are no stopwatch studies of ejaculation
latency in MSM with or without ejaculation con-
cerns. While there is no compelling evidence that
MSM experience ejaculatory dysfunction differ-
ently than their MSW counterparts, more
research is needed.
Psychological Factors
Psychological and interpersonal factors may cause
or exacerbate PE. These factors may be develop-
mental (e.g., sexual abuse, attitudes toward sex
internalized during childhood), individual psycho-
logical factors (e.g., body image, depression,
performance anxiety, alexithymia), and/or rela-
tionship factors (e.g., decreased intimacy, partner
conﬂict) [123–125]. There has been limited
research on causality; most studies have been
cross-sectional and hence can only report associa-
tion. Obviously, developmental variables are
likely to predate clinical PE, but it is conceivable
that an intermediate factor secondary to the devel-
opmental history mediates the development of
PE.
It is plausible that psychological factors may
lead to PE or vice versa. It is likely that for many
men, the relationship is reciprocal with either PE
or the other factor causing exacerbation of the
other. For example, performance anxiety may lead
to PE, which then further exacerbates the original
performance anxiety. (LOE 5d)
Importance of Partners and the Impact of PE on
the Partner’s Sexual Function
Inclusion of the partner in the treatment process is
an important but not a mandatory ingredient for
treatment success [118,126]. Some patients may
not understand why clinicians wish to include the
partner, and some partners may be reluctant to
join the patient in treatment. However, if partners
are not involved in treatment, they may be resis-
tant to changing the sexual interaction. A coopera-
tive partner augments the power of the treatment,
and this likely leads to an improvement in the
couple’s sexual relationship, as well as the broader
aspects of their relationship. There are no con-
trolled studies on the impact of involving partners
in treating PE. However, a review of treatment
studies for ED demonstrates the important role of
including a focus on interpersonal factors on treat-
ment success [127].
Men with PE have been shown to have more
interpersonal difﬁculties than men without PE, as
well as partners of men with PE reporting higher
levels of relationship problems compared with
partners of men without PE [59,128,129]. Men
with PE feel that they are “letting their partner
down” by having PE and that the quality of their
relationship would improve if they did not have
PE [31].
Rosen and Althof reviewed 11 observational,
noninterventional studies from 1997 to 2007 that
reported on the psychosocial and quality of life
consequences of PE on the man, his partner, and
the relationship [130]. These studies employed
different methodologies and outcome measures
and consisted of both qualitative and quantitative
investigations. All studies consistently conﬁrmed a
high level of personal distress reported by men
with PE and their female partners. Men with PE
have signiﬁcantly lower scores on self-esteem and
self-conﬁdence than non-PE men, and one-third
of men with PE report anxiety connected to sexual
situations [131]. The negative impact on single
men with PE may be greater than on men in rela-
tionships as PE serves as a barrier to seeking out
and becoming involved in new relationships [132].
There is evidence of the negative impact of PE
on the female partner’s sexuality. This has been
conﬁrmed in several epidemiological studies
where PE has been found to be correlated to
overall female sexual dysfunction (FSD), sex not
being pleasurable, desire, arousal, and orgasmic
problems as well as low sexual satisfaction and
sexual distress [128,129,131,133–139]. FSD may
also increase the risk of the partner having PE. For
example, Dogan and Dogan [140] found that 50%
of the partners of women with vaginismus were
found to have PE, but it was not possible to deter-
mine whether PE was actually a consequence of
the vaginismus.
Both men and their partners demonstrate nega-
tive effects and interpersonal difﬁculty related to
their PE and an overall reduction in their quality
of life. (LOE 1a–3a)
Assessment of PE
History
Patients want clinicians to inquire about their
sexual health [141]. Often patients are too embar-
rassed, shy, and/or uncertain to initiate a discus-
sion of their sexual complaints in the HCP’s ofﬁce
[142]. Inquiry by the HCP into sexual health gives
patients permission to discuss sexual concerns and
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also screens for associated health risks (e.g., car-
diovascular risk and ED).
Table 3 lists recommended and optional ques-
tions that patients who complain of PE should be
asked [1]. The recommended questions establish
the diagnosis and direct treatment considerations,
and the optional questions gather detail for imple-
menting treatment. Finally, the committee recom-
mends that HCPs take a medical and psychosocial
history. (LOE 5d)
Figure 1 is a ﬂowchart devised by Rowland
et al., detailing the assessment and treatment
options for subjects complaining of PE [143].
Physical Examination
For LPE, a physical examination is advisable but
not mandatory. Some patients ﬁnd it reassuring for
the physician to perform a hands-on physical
examination. For APE, a targeted physical exami-
nation is advisable but not mandatory. The
purpose of a targeted physical examination for the
patient with APE is to assess for comorbidities,
risk factors, and etiologies.
Stopwatch Assessment of Ejaculatory Latency (IELT)
Stopwatch measures of IELT are widely used in
clinical trials and observational studies of PE, but
have not been recommended for use in routine
clinical management of PE [144]. Despite the
potential advantage of objective measurement,
stopwatch measures have the disadvantage of
being intrusive and potentially disruptive of sexual
pleasure or spontaneity [145]. Several studies have
indicated that patient or partner self-report of
ejaculatory latency correlates relatively well with
objective stopwatch latency and might be useful as
a proxy measure of IELT [146–148].
Because patient self-report is the determining
factor in treatment seeking and satisfaction, it is
recommended that self-estimation by the patient
and partner of ejaculatory latency be accepted as
the method for determining IELT in clinical prac-
tice. (LOE 2b)
Use of Assessment Instruments
Standardized assessment measures for PE include
the use of validated questionnaires, in addition to
stopwatch measures of ejaculatory latency [149].
These measures are all relatively new and were
developed primarily for use as research tools.
However, they may serve as valuable adjuncts for
clinical screening and assessment.
Several PE questionnaires assessing lifelong and
acquired subtypes have been described in the lit-
erature [150–155], although only a small number
have undergone extensive psychometric testing
and validation. Five validated questionnaires have
been developed and published to date. Currently,
there are two questionnaires that have extensive
databases and meet most of the criteria for test
development and validation: The Premature
Ejaculation Proﬁle (PEP) and the Index of Prema-
ture Ejaculation (IPE) [150,152]. A third brief
diagnostic measure (Premature Ejaculation Diag-
nostic Tool [PEDT]) has also been developed, has
a modest database, and is available for clinical use
[154]. Two other measures (Arabic and Chinese
PE questionnaires) have minimal validation or
clinical trial data available [151,155]. These latter
measures are not recommended for clinical use.
Table 4 details these instruments in terms of
number of questions, domains, and psychometric
properties. The IPE, PEP, and PEDT can be
found in Appendix 1.
Table 3 Recommended and optional questions to establish the diagnosis of PE and direct treatment
Recommended questions
for diagnosis
What is the time between penetration and ejaculation (cumming)?
Can you delay ejaculation?
Do you feel bothered, annoyed, and/or frustrated by your premature ejaculation?
Optional questions:
Differentiate lifelong and acquired PE
When did you first experience premature ejaculation?
Have you experienced premature ejaculation since your first sexual experience on
every/almost every attempt and with every partner?
Optional questions:
Assess erectile function
Is your erection hard enough to penetrate?
Do you have difficulty in maintaining your erection until you ejaculate during intercourse?
Do you ever rush intercourse to prevent loss of your erection?
Optional questions:
Assess relationship impact
How upset is your partner with your premature ejaculation?
Does your partner avoid sexual intercourse?
Is your premature ejaculation affecting your overall relationship?
Optional question:
Previous treatment
Have you received any treatment for your premature ejaculation previously?
Optional questions:
Impact on quality of life
Do you avoid sexual intercourse because of embarrassment?
Do you feel anxious, depressed, or embarrassed because of your premature ejaculation?
PE = premature ejaculation
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Depending on the speciﬁc need, the PEP or
IPE continue to be the preferred questionnaire
measures for assessing lifelong or acquired sub-
types of PE, particularly when monitoring respon-
siveness to treatment. Overall, these measures may
serve as useful adjuncts but should not substitute
for a detailed sexual history performed by a quali-
ﬁed clinician. (LOE 2b).
Psychological/Behavioral, Combined Medical and
Psychological, and Educational Interventions
Psychotherapy for men and couples suffering from
PE has two overlapping goals. First, psychological
interventions aim to help men develop sexual skills
that enable them to delay ejaculation while broad-
ening their sexual scripts, increasing sexual self-
conﬁdence, and diminishing performance anxiety.
The second goal focuses on resolving psychologi-
cal and interpersonal issues that may have precipi-
tated, maintained, or be the consequence of the
PE symptom for the man, partner, or couple
[156–158].
Present day psychotherapy for rapid ejaculation
is an integration of psychodynamic, systems,
behavioral, and cognitive approaches within a
short-term psychotherapy model [7,157,159–161].
Treatment may be provided in an individual,
couples, or group format. Unfortunately, the
majority of the psychotherapy treatment outcome
studies are uncontrolled, unblinded trials; few
meet the requirements for evidence-based studies
[156]. Most studies employed small to moderately
sized cohorts who received different varieties of
psychological interventions with limited or no
follow-up. Additionally, the inclusion criteria uti-
lized by these studies varied widely and included
men who would not meet the ISSM PE deﬁnition.
The most frequently used behavioral treat-
ments are the squeeze or stop–start techniques
[6,162]. Both of these therapies were designed
to help men recognize mid-level ranges of
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• Perceived degree of ejaculatory control
• Degree of patient/partner distress
• Onset and duration of PE
• Psychosocial history
• Medical history
• Physical examination 
NO
SUBJECTIVE PE
VARIABLE
PE
TREATMENT
Reassurance
Education
Psychotherapy
Behavioral Therapy
YES
PREMATURE EJACULATION
YES
PE SECONDARY TO ED OR
OTHER SEXUAL DYSFUNCTION
MANAGE PRIMARY CAUSE
YES
NO
ACQUIRED PE LIFELONG PE
TREATMENT
BEHAVIORAL/PSYCHOTHERAPY
PHARMACOTHERAPY
COMBINATION TREATMENT
PATIENT
PREFERENCE
TREATMENT
PHARMACOTHERAPY
BEHAVIORAL/PSYCHOTHERAPY
COMBINATION TREATMENT
ATTEMPT GRADUATED WITHDRAWAL OF DRUG THERAPY WHEN  APPROPRIATE
Figure 1 Algorithm for the management of PE (with permission of D. Rowland). ED = erectile dysfunction; PE = premature
ejaculation
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excitement. Men gain skills at identifying mid-
level excitement by a series of graduated exercises
beginning with self-stimulation, moving on to
partner-hand stimulation, then to intercourse
without movement, and ﬁnally to stop/start
thrusting. This process gradually leads to an
increase in IELT, sexual conﬁdence, and self-
esteem; although there are few controlled studies
to support this claim.
Older uncontrolled studies on the squeeze
technique report a failure rate of 2.2% immedi-
ately after therapy and 2.7% at the 5-year
follow-up [6]. These results have not been repli-
cated; other studies have found success rates of
between 60% and 90% [163]. De Carufel and
Trudel demonstrated an eightfold increase in
IELT among men treated with behavioral
techniques compared with a wait-list control
condition [164]. A previous study found that
bibliotherapy with and without phone contact as
well as sex therapy (three separate groups) expe-
rienced a sixfold increase in IELT compared with
a control group [165]. Treatment gains were
maintained at the 3 months follow-up.
There have been two recent meta-analytic
reports and one systematic review on psycho-
therapy for sexual dysfunctions [166–168]. The
ﬁrst reviewed only one PE psychotherapy article
and three PE combination medical and psycho-
therapy studies [167]. The authors concluded that
“there is weak and inconsistent evidence regard-
ing the effectiveness of psychological interven-
tions for the treatment of premature ejaculation.”
Similarly, the second study [166] only reviewed
the same report and concluded that “there was no
evidence for the efﬁcacy of psychological inter-
ventions on symptom severity in patients suffer-
ing from PE.” The third review found evidence
that behavioral interventions were effective in
treating PE [168]. Because these meta-analyses
had such stringent inclusion criterion, the major-
ity of the PE psychotherapy studies were not
included and thus the conclusions were based on
a small number of studies. The PE Guidelines
Committee continues to believe that psycho-
therapy offers men, women, and couples beneﬁt,
including the development of sexual skills, delay
of ejaculation, improving relationship concerns,
and sexual self-conﬁdence.
There is some evidence to support the efﬁcacy
of psychological and behavioral interventions in
the treatment of PE (LOE 2b). Future well-
designed studies on the efﬁcacy of psychotherapy
are needed.Ta
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Men with VPE (irregular and inconsistent rapid
ejaculation with a diminished sense of subjective
control of ejaculation) should be educated and
reassured. Men with SPE (those whose IELT is
within the normal range but who are preoccupied
by their ejaculatory control) may require a referral
for psychotherapy [10]. More research is necessary
to better deﬁne the efﬁcacy of reassurance, educa-
tion, and psychotherapy with these provisional
subtypes.
HCPs and mental health professionals have dif-
fering levels of interest and training in treating PE.
In general, all clinicians should be able to diag-
nose, offer support, and prescribe behavioral exer-
cises. When the situation is complex and/or
patients are not responsive to the initial interven-
tion, clinicians should consider referring to a
sexual health specialist.
Online Treatment Programs
A recent development in the psychological treat-
ment of male and female sexual dysfunction has
been the adaptation of strategies used in face-to-
face treatment to online treatment packages.
McCabe et al. [169] evaluated their six-session
online treatment for ED and found it to be an
effective treatment for ED and a suitable alterna-
tive to face-to-face therapy. Similar ﬁndings have
been obtained for Internet-based treatment for
FSD [170]. Although there are currently no
Internet-based programs available speciﬁcally for
PE, these other programs could serve as a model
for the development of such online interventions.
As for other sexual disorders, this would be an
extremely useful future development in the treat-
ment of PE.
Pharmacological Treatment
Several forms of pharmacotherapy have been used
in the treatment of PE [171]. These include the
use of topical local anesthetics (LA) [172], selective
serotonin reuptake inhibitors (SSRIs) [57,174],
tramadol [175], phosphodiesterase type 5 inhibi-
tors (PDE5i) [176], and alpha adrenergic blockers
[177]. The use of topical LA, such as lidocaine,
prilocaine, or benzocaine, alone or in association,
to diminish the sensitivity of the glans penis is the
oldest known pharmacological treatment for PE
[60]. The introduction of the SSRIs paroxetine,
sertraline, ﬂuoxetine, citalopram, and the tricyclic
antidepressant (TCA) clomipramine has revolu-
tionized the treatment of PE. These drugs block
axonal reuptake of serotonin from the synaptic
cleft of central serotonergic neurons by 5-HT
transporters, resulting in enhanced 5-HT neuro-
transmission and stimulation of postsynaptic
membrane 5-HT receptors.
Treatment with SSRIs and TCAs
PE can be treated with on-demand SSRIs such as
dapoxetine or off-label clomipramine, paroxetine,
sertraline, and ﬂuoxetine, or with daily dosing of
off-label paroxetine, clomipramine, sertraline,
ﬂuoxetine, or citalopram [63,178–187].
Dapoxetine
Dapoxetine has received approval for the treatment
of PE in over 50 countries worldwide. It is a rapid-
acting and short half-life SSRI with a pharmacoki-
netic proﬁle supporting a role as an on-demand
treatment for PE [181,182,184,188,189].No drug–
drug interactions associated with dapoxetine,
including phosphodiesterase inhibitor drugs, have
been reported [190]. In randomized controlled
trials (RCTs), dapoxetine 30 mgor 60 mg taken 1–2
hours before intercourse is more effective than
placebo from the ﬁrst dose, resulting in a 2.5 and
3.0-fold increases in IELT, increased ejaculatory
control, decreased distress, and increased satisfac-
tion. Dapoxetine was comparably effective both in
men with LPE and APE [114,184,191] and was
similarly effective and well tolerated in men with
PE and comorbid ED treated with PDE5i drugs
[192]. Treatment-related side effects were uncom-
mon, dose dependent, and included nausea, diar-
rhea, headache, and dizziness [184,189]. They were
responsible for study discontinuation in 4%
(30 mg) and 10% (60 mg) of subjects. There was no
indication of an increased risk of suicidal ideation or
suicide attempts and little indication of withdrawal
symptoms with abrupt dapoxetine cessation
[193].
There is Level 1a evidence to support the efﬁ-
cacy and safety of on-demand dosing of dapoxetine
for the treatment of lifelong and APE. (LOE 1a)
Off-Label SSRIs and TCAs
Daily treatment with off-label paroxetine
10–40 mg, clomipramine 12.5–50 mg, sertraline
50–200 mg, ﬂuoxetine 20–40 mg, and citalopram
20–40 mg is usually effective in delaying ejacula-
tion [178–180,183,186,194]. A meta-analysis of
published data suggests that paroxetine exerts
the strongest ejaculation delay, increasing IELT
approximately 8.8-fold over baseline [195].
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Ejaculation delay usually occurs within 5–10
days of starting treatment, but the full therapeutic
effect may require 2–3 weeks of treatment and is
usually sustained during long-term use [196].
Adverse effects are usually minor, start in the ﬁrst
week of treatment, and may gradually disappear
within 2–3 weeks. They include fatigue, yawning,
mild nausea, diarrhea, or perspiration. There are
anecdotal reports that decreased libido and ED are
less frequently seen in nondepressed PE men
treated by SSRIs compared with depressed men
treated with SSRIs [197]. Men wishing to impreg-
nate their partners should be advised that SSRIs
may affect the motility of spermatozoa and there-
fore should not begin treatment with an SSRI, or if
on an SSRI, gradually discontinue taking it [198].
Neurocognitive adverse effects include signiﬁcant
agitation and hypomania in a small number of
patients, and treatment with SSRIs should be
avoided in men with a history of bipolar depres-
sion [199].
Systematic analysis of RCTs of antidepressants
(SSRIs and other drug classes) in patients with
depressive and/or anxiety disorders indicates a
small increase in the risk of suicidal ideation or
suicide attempts in youth but not adults [200–202].
In contrast, such risk of suicidal ideation has not
been found in trials with SSRIs in nondepressed
men with PE [200–202]. Caution is suggested in
prescribing SSRIs to young adolescents with PE
aged 18 years or less and to men with PE and a
comorbid depressive disorder, particularly when
associated with suicidal ideation [200]. Patients
should be advised to avoid sudden cessation or
rapid dose reduction of daily dosed SSRIs, which
may be associated with an SSRI withdrawal syn-
drome [203].
On-demand administration of clomipramine,
paroxetine, sertraline, and ﬂuoxetine 3–6 hours
before intercourse is modestly efﬁcacious and well
tolerated but is associated with substantially less
ejaculatory delay than daily treatment in most
studies [185,187,204,205]. On-demand treatment
may be combined with either an initial trial of
daily treatment or concomitant low-dose daily
treatment [185].
Patients are often reluctant to begin off-label
treatment of PE with SSRIs. Salonia et al. reported
that 30% of patients refused to begin treatment
(paroxetine 10 mg daily for 21 days followed by
20 mg as needed) and another 30% of those that
began treatment discontinued it [206]. Similarly,
Mondaini et al. reported that in a clinic population,
90% of subjects either refused to begin or discon-
tinued dapoxetine within 12 months of beginning
treatment [207]. Reasons given included not
wanting to take an antidepressant, treatment effects
below expectations, and cost.
There is Level 1a evidence to support the efﬁ-
cacy and safety of off-label daily dosing of the SSRIs
paroxetine, sertraline, citalopram, ﬂuoxetine, and
the serotonergic tricyclic clomipramine, and
off-label on-demand dosing of clomipramine,
paroxetine, and sertraline for the treatment of LPE
and APE. (LOE 1a)
The decision to treat PE with either
on-demand dosing of dapoxetine (where available)
or daily dosing of off-label SSRIs should be based
upon the treating physician’s assessment of indi-
vidual patient requirements. Although many men
with PE who engage in sexual intercourse infre-
quently may prefer on-demand treatment, many
men in established relationships may prefer the
convenience of daily medication [208]. Well-
designed preference trials will provide additional
insight into the role of on-demand dosing.
In some countries, off-label prescribing may
present difﬁculties for the physician as the regula-
tory authorities strongly advise against prescribing
for indications in which a medication is not
licensed or approved. Obviously, this complicates
treatment in countries where there is no approved
medication and the regulatory authorities advise
against off-label prescription.
Topical Local Anesthetics
The use of topical LA such as lidocaine and/or
prilocaine as a cream, gel, or spray is well estab-
lished and is moderately effective in delaying
ejaculation [172,173,209–211]. Data suggest that
diminishing the glans sensitivity may inhibit the
spinal reﬂex arc responsible for ejaculation [212].
Dinsmore et al. reported on the use of PSD502, a
lidocaine–prilocaine spray currently in clinical
trials that is applied to the penis at least 5 minutes
before intercourse. The treated group reported a
6.3-fold increase in IELT and associated improve-
ments in PRO measures of control and sexual sat-
isfaction [172]. Carson et al. reported similar
results in a second Phase 3 randomized controlled
trial. There were minimal reports of penile
hypoanesthesia and transfer to the partner due to
the unique formulation of the compound [172].
Other topical anesthetics are associated with sig-
niﬁcant penile hypoanesthesia and possible
transvaginal absorption, resulting in vaginal numb-
ness and resultant female anorgasmia unless a
condom is used [210].
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There is Level 1a evidence to support the efﬁ-
cacy and safety of off-label on-demand label
topical anesthetics in the treatment of LPE. (LOE
1a)
PDE5i
PDE5i, sildenaﬁl, tadalaﬁl, and vardenaﬁl are
effective treatments for ED. Several authors have
reported using PDE5is alone or in combination
with SSRIs as a treatment for PE [176,213–215].
Although systematic reviews of multiple studies
have failed to provide robust evidence to support a
role for PDE5i in the treatment of PE, with the
exception of men with PE and comorbid ED
[216,217], recent well-designed studies do support
a potential role for these agents suggesting a need
for further evidence-based research [176,216].
There is some evidence to support the efﬁcacy
and safety of off-label on-demand or daily dosing
of PDE5is in the treatment of LPE in men with
normal erectile function (LOE 4d). Treatment of
LPE with PDE5is in men with normal erectile
function is not recommended, and further
evidence-based research is encouraged to under-
stand conﬂicting data.
Table 5 is a summary of recommended pharma-
cological treatments for PE.
Other Pharmacological Treatments
Tramadol
Tramadol has been investigated as a potential off-
label therapy for PE, with several studies demon-
strating efﬁcacy. The major metabolite, M1, has a
200-fold increased afﬁnity for the μ-opioid recep-
tor, which likely accounts for the analgesic effects
achieved [218]. Because of the relatively long half-
lives of tramadol (6 hours) and the M1 metabolite
(9 hours), patients may be at decreased risk of
developing addiction compared with other
μ-opioid receptor agonists. These pharmacoki-
netic properties require dose adjustment in
patients with hepatic or renal impairments.
Although the mechanism of action is not com-
pletely described, the efﬁcacy of tramadol may be
secondary to anti-nociceptive and anesthetic-like
effects, as well as via central nervous system modu-
lation through inhibition of serotonin and
noradrenaline reuptake [218–220].
Several studies have demonstrated improved
IELTs with varying doses of daily or on-demand
tramadol therapy. The ﬁrst reported use of on
demand tramadol for PE evaluated 64 patients
in a blinded, randomized trial. A 50 mg dose
vs. placebo was administered 2 hours prior to Ta
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anticipated sexual activity over an 8-week period
[219]. Results demonstrated an absolute increase
in IELT from 19–21 seconds pretreatment to 243
seconds posttreatment (placebo 34 seconds,
P < 0.001). Satisfaction was similarly improved
with tramadol over placebo, as measured by the
satisfaction domain of the International Index of
Erectile Function questionnaire (14 vs. 10,
P < 0.05).
Three subsequent investigations evaluated
on-demand tramadol using blinded, crossover, and
placebo-controlled study designs [175,221,222].
Following administration of 25–50 mg of tramadol
over an 8–12-week period, patients experienced a
4–7.3-fold increase in IELT from baseline com-
pared with a 1.7-1.8 fold increase with placebo
(absolute change from 36–70 to 155–442 seconds)
[175,222]. Alghobary and colleagues further inves-
tigated temporal beneﬁts of therapy and reported
slight attenuation of efﬁcacy over time [221].
Results demonstrated a 7.2-fold increase (18
seconds pretreatment to 130 seconds) at 6 weeks of
tramadol 50 mg, which decreased to 5.7-fold
increase (102 seconds) at 12 weeks (P = 0.02
between time points). In comparing efﬁcacy with
paroxetine, patients receiving daily paroxetine
achieved an 11.1-fold improvement (6 weeks),
which further increased to 22.1-fold improvement
(12 weeks). These ﬁndings suggest a need for
further long-term and comparative evaluations to
assess the efﬁcacy of tramadol over time and
against alternative therapies.
In the largest, blinded, placebo-controlled ran-
domized trial performed to date, Bar-Or and
colleagues evaluated the efﬁcacy of orally disinte-
grating tramadol (62 mg and 89 mg) administered
within 2 minutes of anticipated intercourse [223].
Results from 604 patients over 12 weeks of therapy
demonstrated a clinically small, although statisti-
cally signiﬁcant improvement in IELT (1.6, 2.4,
and 2.5-fold increases for placebo, 62 mg and
89 mg, respectively) (P < 0.001 for all compari-
sons). A more recent study, evaluating 300 patients
randomized to tramadol hydrochloride capsules
25, 50, or 100 mg demonstrated a dose-response
effect [224]. Reported IELT increased from a
mean of 174 seconds pretreatment to 790 (25 mg),
1,405 (50 mg), and 2,189 (100 mg) seconds, equat-
ing to a 4.5, 8.1, and 12.6-fold increase, respec-
tively. Although the absolute increase in IELT was
signiﬁcantly elevated compared with other con-
temporary studies, this may be secondary to higher
baseline IELTs with the study population (mean
174 seconds, standard deviation 54 seconds). See
Table 6 for a summary of available studies evalu-
ating the efﬁcacy of tramadol on demand for the
off-label treatment of PE.
Tramadol may be an effective option for the
treatment of PE. However, it may be considered
when other therapies have failed because of the
risk of addiction and side effects. It should not be
combined with an SSRI because of the risk of
serotonin syndrome, a potentially fatal outcome
[225]. Further well-controlled studies are required
to assess the efﬁcacy and safety of tramadol in the
treatment of PE patients. (LOE2)
Oxytocin
Oxytocin has been found to shorten ejaculation
latency and post-ejaculatory refractory period
when it is infused into the cerebral ventricle of
male rats and increases latencies of mount and
intromission when administered into the
intracerebroventricular space [226,227]. Similar to
central administration, systemic oxytocin adminis-
tration is demonstrated to shorten ejaculation
latency and post-ejaculatory interval in sexually
active male rats [226,227]. These ﬁndings sug-
gested a potential role for anti-oxytocin drugs in
treatment of PE. Argiolas et al. demonstrated that
central administration of a selective oxytocin
receptor antagonist inhibits sexual behavior,
including ejaculation, in male rats [228]. Clement
et al. conﬁrmed that intraventricular administra-
tion of oxytocin antagonist dose-dependently
inhibited sexual responses, whereas they also
found that systemic administration of oxytocin
antagonist did not make a signiﬁcant change [229].
In a recent study, the same group demonstrated
that a highly selective, non-peptide oxytocin
antagonist (GSK557296) inhibits ejaculation when
administered both peripherally and centrally [75].
The authors concluded that targeting central
oxytocin receptors with a highly selective antago-
nist might be a promising approach for the treat-
ment of PE.
A double-blind, placebo control study of
epelsiban, a selective oxytocin receptor antagonist,
failed to show either clinical or statistical differ-
ences in IELT from placebo in men with PE [230].
In an attempt to investigate the effects of
polymorphisms in oxytocin and vasopressin recep-
tor genes on ejaculatory function, Jern et al. could
not detect any clear-cut gene variant revealing
ejaculatory dysfunction and concluded that
oxytocin receptor genes are unlikely targets for
future pharmaceutical treatment of PE [92].
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Intraventricular administration of oxytocin
antagonist inhibits sexual behavior in animal
studies; however in one human study, an oxytocin
antagonist failed to clinically or statistically
improve IELT. Further human studies are neces-
sary. (LOE 4)
Cryoablation and Neuromodulation of the Dorsal
Penile Nerve
Ablation and modulation of the dorsal penile
nerve, which is the main afferent somatosensory
pathway of the penis [231], have been suggested to
be an effective treatment option for PE [232,233].
David Prologo et al. [232] reported on the unilat-
eral computed tomography-guided percutaneous
cryoablation of the dorsal penile nerve on IELT
and PEP outcomes in 24 men with PE. Baseline
average IELT signiﬁcantly increased (from
54.7 ± 7.8 to 140.9 ± 83.6 at the end of the ﬁrst
year, P < 0.001) and PEP results were also
improved. The authors noted that the majority of
the subjects said that they would undergo the pro-
cedure again.
In another study, Basal et al. [233] investigated
the clinical utility of percutaneous pulsed
radiofrequency ablation of bilateral dorsal penile
nerves in 15 patients with LPE. The authors
described a signiﬁcant increase in the mean
IELT 3 weeks after the procedure (18.5 ± 17.9
vs. 139.9 ± 55.1 seconds) and PRO measures
improved. However, further expanded clinical
trials are necessary before such modalities can be
recommended for treating PE.
Neuromodulation of the dorsal penile nerve is
an invasive and irreversible procedure, which is
associated with an increase in the IELT. However,
safety of this treatment modality needs to be deter-
mined before this procedure can be recommended
for treating PE patients. (LOE 4)
Intracavernosal Injection for PE
There is limited evidence regarding the efﬁcacy of
intracavernosal vasoactive drug injection for the
treatment of PE. In one study, which included
eight PE patients, a mixture of phentolamine
mesylate (1.0 mg/mL) and papaverine hydrochlo-
ride (30 mg/mL) was injected. All patients
reported satisfaction with the results of this treat-
ment, but ejaculation delay was not objectively
measured [234].
Intracavernosal injection of vasoactive drugs is
not recommended for the treatment of PE.
(LOE 4)Ta
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Acupuncture
One randomized placebo-controlled clinical study
compared effectiveness of acupuncture therapy
(twice a week) with paroxetine (20 mg/day) and
placebo (sham acupuncture) in the treatment of
PE [235]. The authors included 90 patients with
PE and demonstrated that acupuncture had a sig-
niﬁcantly stronger ejaculation delaying effect than
placebo (65.7 vs. 33.1 seconds), although it was less
effective than daily paroxetine (82.7 seconds)
(P = 0.001). Similarly, the PRO measures showed
an improvement in the acupuncture and
paroxetine groups.
There are limited positive data regarding the
effectiveness of acupuncture therapy. (LOE 3b)
Preclinical Studies for PE
Several agents have been studied in animal
models for treating PE. A potent SSRI (DA-
8031) signiﬁcantly inhibited ejaculation after oral
and intravenous administration in both para-
chloroamphetamine and meta-chlorophenyl-
piperazine-mediated ejaculation rat models [236].
In another study using a rat model, DA-8031
administration resulted in inhibition of the expul-
sion phase of ejaculation by bulbospongiosus
muscle activity modulation and impairment of
the emission phase by blocking the seminal
vesicular pressure rise [237].
Modaﬁnil (diphenylmethyl sulphinyl-2-
acetamide) is an agent that is used for the treat-
ment of narcolepsy. In a behavioral rat model,
Marson et al. [238] demonstrated that modaﬁnil
(30 mg/kg and 100 mg/kg) produced a signiﬁcant
delay in ejaculation. The delay in ejaculation was
accompanied by an increase in the number of
intromissions without any change in the mount or
intromission latency.
Because the bulbospongiosus muscle plays a
pivotal role in the expulsion phase of ejaculation,
decreasing its contractile activity with injection of
botulinum toxin may be of beneﬁt in treating PE
[239]. In an animal model Serefoglu et al. [240]
demonstrated that botulinum toxin A injection
(0.5–1 U/mL) into the bulbospongiosus muscle
bilaterally signiﬁcantly increased ejaculatory
latency in male rats.
Combining Psychological and
Pharmacological Treatment
Combining medical and psychological interven-
tions harnesses the power of both therapies to
provide patients with rapid symptom amelioration,
while the psychological and interpersonal issues
that either precipitated or maintained the
symptom are addressed [143,157,241,242]. There
are three studies reporting on combined pharma-
cological and behavioral treatment for PE [243–
245] and one study reporting on consecutive
treatment with pharmacotherapy followed by
behavior therapy [246]. Each study used a different
medication—sildenaﬁl, citalopram, clomipramine,
or paroxetine (in the consecutive study). Phar-
macotherapy was given in conjunction with a
behavioral treatment and compared with
pharmacotherapy alone. In all three studies, com-
bination therapy was superior to pharmacotherapy
alone on either IELT and/or the Chinese IPE.
For ED, combined treatments have also been
found to be more effective than either medical or
psychological treatments alone [167,247,248].
Factors that are not addressable by
pharmacotherapy alone can be attended to such as:
(i) patient factors (performance anxiety, self-
conﬁdence); (ii) partner factors (partner sexual
dysfunction); (iii) relationship factors (conﬂict,
lack of communication); (iv) sexual factors in the
relationship (sexual scripts, sexual satisfaction);
and (v) contextual factors (life stressors).
Combining a medical and psychological
approach may be especially useful in men with
APE where there is a clear psychosocial precipitant
or lifelong cases where the individual or couple’s
issues interfere in the medical treatment and
success of therapy. Similarly, in men with PE and
comorbid ED, combination therapy may also be
helpful to manage the psychosocial aspects of these
sexual dysfunctions. (LOE 2a)
Role of Education and Coaching
Education (or coaching) on PE may be useful to
attend to aspects of PE that are not treated with
medication [157,241,242,249]. Providing educa-
tion on the prevalence of PE and general popula-
tion IELT may help to dispel myths. Additionally,
education may help men with PE to not avoid
sexual activity, to discuss issues with their partner,
or limit their sexual repertoire.
Educational or coaching strategies are designed
to give the man the conﬁdence to try the medical
intervention, reduce performance anxiety, and
modify his maladaptive sexual scripts. (LOE 5d)
Lifelong PE
As LPE is likely to have an organic etiology, a
medical intervention with basic psycho-education
is initially recommended [10,250].
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If the PE has resulted in psychological and rela-
tionship concerns, graded levels of patient and
couple counseling, guidance, and/or relationship
therapy may be a useful adjunct to the medical
intervention. (LOE 1a)
Acquired PE
It is recommended that HCPs utilize a combina-
tion medical and psychological approach where
feasible [251]. Men desire an immediate effect
from therapy; therefore pharmacotherapy and
amelioration of associated disease factors such as
ED will be extremely helpful.
Education on the nature of PE, helping men
improve ejaculatory control with behavioral exer-
cises, addressing restricted/narrow sexual behav-
ioral patterns, and resolving interpersonal issues
are likely to be of signiﬁcant help to men with
APE. Once the man’s self conﬁdence and sense of
control have improved, it may then be possible to
reduce or discontinue the medical intervention.
(LOE 5d)
Role of the Primary Care Clinician
Primary care providers are usually the ﬁrst line of
contact for a patient with the health care system,
including for the diagnosis and management of
sexual problems. This role includes (i) initial rec-
ognition and evaluation of any undiagnosed sign,
symptom, or health concern (the “undifferenti-
ated” patient); (ii) health promotion including
disease prevention, health maintenance, counsel-
ing, patient education, chronic illness manage-
ment, and patient advocacy; and (iii) coordination
of care promoting effective communication with
patients and encouraging the patient to be a
partner in health [252]. This model of care is
not limited by problem origin, organ system, or
diagnosis.
Primary care providers (PCP) are the ideal
group to assist the patient with sexual difﬁculties
for several reasons including: (i) the value of the
longitudinal and personal relationships with
patients; (ii) the multifactorial issues around sexual
problems that can be appropriately evaluated by a
generalist clinician; and (iii) the long-term
follow-up routine in primary care is well suited to
being certain that a sexual dysfunction is resolved.
The main responsibility of the PCP is to recognize
PE and enable the patient to feel comfortable
about getting help, either in the primary care
setting or through an effective referral. PCPs can
normalize and universalize the inquiry about
sexual concerns and then use screening questions
to identify PE. PCPs who have effective commu-
nication skills regarding sexual function and who
are knowledgeable about ﬁrst-line treatments can
initiate the workup and treatment plan.
A urologist can be useful when the patient
presents with a difﬁcult or complex problem,
with a genital anatomic problem, with prostatitis
or lower urinary tract symptom, or with ED or
painful intercourse due to a structural condition
such as phimosis. The endocrinologist is useful in
the presence of sexual dysfunctions comorbid
with hormonal and metabolic abnormalities. A
mental health professional with experience in
sexual problems can work collaboratively with the
clinician by: (i) resolving the sexual difﬁculty; (ii)
teasing out important history; (iii) educating the
patient and partner; (iv) suggesting sexual
enhancement techniques; and (v) helping the
couple resolve individual as well as relationship
problems.
Referral to or collaboration with a psychologist
or sexual health specialist may be appropriate at
various times when managing a man with PE. The
major factors in determining when a consultation
is needed include (i) the PCP’s comfort in discuss-
ing PE and managing treatment options; (ii) the
depth of the psychosocial and sexual issues
involved; and (iii) the success or failure of the
PCPs initial intervention efforts. Speciﬁc instances
in which subspecialty assistance is often useful
include (i) treatment failure; (ii) anatomic or
complex hormonal issues; (iii) complex issues
around sex and/or partnerships; (iv) severe psycho-
logical problems; or (v) anytime the treating phy-
sician feels that help is needed.
The management algorithm “ALLOW,” an
outgrowth of the PLISSIT model (permission,
limited information, speciﬁc suggestions, and
intensive therapy) [253] can help PCPs talk with
their patients about sexual health problems and
refer patients when appropriate [254]. The physi-
cian begins by “Asking” about a patient’s sexual life
and “Legitimizing” the importance and potential
impact of sexual problems to the patient. The phy-
sician then considers his/her “Limitations” with
regard tomanaging the sexual dysfunction andmay
refer the patient to a sexual health specialist for
further evaluation and management. Conversely, if
the physician feels comfortable managing the
patient’s issue(s), he or she then “Opens” up the
issue(s) for further discussion, and the physician
and the patient “Work together to develop a man-
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agement plan.”Thismethodical approach to giving
the patient permission to discuss sexual issues can
be accomplished in as brief or as long a time as the
physician has available.
Comanagement by the less experienced PCP
along with an appropriate sexual health specialist
is an excellent way to manage the patient’s issues
and to increase the PCPs understanding of PE.
Table 7 Summary of PE guideline recommendations
Topic Recommendation
Definition of
lifelong PE
A male sexual dysfunction characterized by ejaculation that always or nearly always occurs prior to or within
about 1 minute of vaginal penetration, either present from the first sexual experience or following a new
bothersome change in ejaculatory latency, and the inability to delay ejaculation on all or nearly all vaginal
penetrations, and negative personal consequences, such as distress, bother, frustration, and/or the avoidance
of sexual intimacy.
Prevalence of PE Based on these data and the ISSM and DSM-5 definition of PE, in terms of an IELT of about 1 minute, the
prevalence of lifelong PE is unlikely to exceed 4% of the general population.
Average ejaculatory
latency
In multinational studies, the median IELT is 5.4 minutes. Median IELT may differ between countries.
Quality of life Negative effects on quality of life and interpersonal difficulty related to their PE have been consistently been
reported by men and their partners.
Etiology The etiology of premature ejaculation is not known. To date, no biological factor has been shown to be causative
in the majority of men with PE.
Assessment The committee agreed that there was inadequate evidence to recommend screening or case finding for PE, either
in a general population or in any subpopulation. However, it is recommended that men with ED be screened for
PE.
It is recommended that clinicians utilize the screening questions in Table 3 and that clinicians take a medical and
psychosocial history.
Because patient self-report is the determining factor in treatment seeking and satisfaction, it has been
recommended that self-estimation by the patient and partner of ejaculatory latency be routinely assessed in
clinical practice when PE is present.
The PEP or IPE are currently the preferred questionnaire measures for assessing PE, particularly in the context
of monitoring responsiveness to treatment.
For lifelong PE, a physical examination is highly advisable but not mandatory and should be conducted in most if
not all patients.
For acquired PE, a targeted physical examination is mandatory to assess for associated/causal diseases such as
ED, thyroid dysfunction, or prostatitis.
Treatment There is robust evidence to support the efficacy and safety of on-demand dosing of dapoxetine for the treatment
of lifelong and acquired PE. It has been approved in some countries.
There is robust evidence to support the efficacy and safety of off-label daily dosing of the SSRIs paroxetine,
sertraline, citalopram, fluoxetine, and the serotonergic tricyclic clomipramine, and off-label on-demand dosing of
clomipramine, paroxetine, and sertraline for the treatment of lifelong and acquired PE.
There is good evidence to support the efficacy and safety of off-label on-demand topical anesthetics in the
treatment of lifelong PE.
There is some evidence to support the efficacy and safety of off-label on-demand or daily dosing of PDE5is in the
treatment of lifelong PE in men with normal erectile function. Treatment of lifelong PE with PDE5is in men with
normal erectile function is not recommended, and further evidence-based research is encouraged to further
understand conflicting data.
Tramadol may be an effective option for the treatment of PE. However, it may be considered when other
therapies have failed because of the risk of addiction and side effects. It should not be combined with an SSRI
because of the risk of serotonin syndrome, a potentially fatal outcome. Further, well-controlled studies are
required to assess the efficacy and safety of tramadol in the treatment of PE patients.
There is modest evidence supporting the efficacy of psychological/behavioral interventions in the treatment of PE.
Combining pharmacological and psychological/behavioral treatments may be especially useful in men with
acquired premature ejaculation where there is a clear psychosocial precipitant or lifelong cases where the
individual or couple’s responses to PE are likely to interfere in the medical treatment and ultimate success of
therapy. Similarly, in men with PE and comorbid ED, combination therapy may also be helpful to manage the
psychosocial aspects of these sexual dysfunctions.
There is reliable evidence to support the treatment of PE and comorbid ED with ED pharmacotherapy. There is
Level 3c evidence to support the treatment of PE and comorbid ED with ED pharmacotherapy in combination
with PE pharmacotherapy.
Selective dorsal nerve neurotomy or glans penis augmentation using hyaluronic acid gel may be associated with
permanent loss of sexual function and is not recommended in the management of PE.
Outcome Treatment outcome can be addressed in one simple, brief, and validated question known as the Clinical Global
Impression of Change (CGIC). It asks patients, “Compared to before starting treatment, would you describe
your premature ejaculation problem as: much worse, worse, slightly worse, no change, slightly better, better, or
much better?”
DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; ED = erectile dysfunction; IELT = intravaginal ejaculatory latency time; ISSM = Inter-
national Society of Sexual Medicine; IPE = Index of Premature Ejaculation; PDE5i = phosphodiesterase type 5 inhibitor; PE = premature ejaculation; PEP = Pre-
mature Ejaculation Profile; SSRI = selective serotonin reuptake inhibitor
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Good communication between clinicians can
improve patient outcomes and understanding of
planned treatments and monitoring measures.
Comanagement can be optimized by a clear
understanding between the PCP and the sexual
health specialist about who will do what. This
kind of communication can be ensured by creat-
ing “referral agreements” in which a speciﬁc
referral guideline is used and the responsibilities
and activities of each clinician are clearly spelled
out [255].
Conclusion
In 2009, the ISSM convened a select panel of
experts to develop an evidence-based set of guide-
lines for patients suffering from LPE [1]. That
document concluded by recognizing the continu-
ally evolving nature of clinical research and rec-
ommended a subsequent guideline review and
revision every fourth year.
As per that recommendation, the ISSM con-
vened a second multidisciplinary panel of experts
in April 2013. This manuscript summarizes the
committee’s work in reviewing and updating the
original recommendations. Table 7 lists all the rel-
evant recommendations promulgated by the
second PE Guidelines Committee including issues
of deﬁnition, prevalence, subtypes, etiology,
assessment, and treatment.
Development of guidelines is an evolutionary
process that continually reviews data and incorpo-
rates the best new research. We expect that future
research will lead to a more complete under-
standing of the pathophysiology as well as new
efﬁcacious and safe treatments for this sexual dys-
function. Therefore, it is strongly recommended
that these guidelines again be reevaluated and
updated in 4 years.
Finally, it is important to keep in mind that
PE causes signiﬁcant personal and interpersonal
distress to the man, his partner, and the couple.
We are hopeful that these guidelines will assist
clinicians in accurately diagnosing and managing
their patients who present with complaints of
PE.
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Appendix 1
Index of Premature Ejaculation (IPE)
These questions ask about the effects your sexual problems have had on your sex life over the past 4 weeks. Please answer the following
questions as honestly and clearly as possible. In answering these questions, the following deﬁnitions apply:
• Sexual intercourse is deﬁned as vaginal penetration (you entered your partner).
• Ejaculation is the ejection of semen from the penis.
• Control is ejaculating when you are ready.
• Distress means how frustrated, disappointed, or bothered you are by your premature ejaculation.
Mark only one box per question.
1) Over the past 4 weeks, when you had sexual intercourse, how often did you have control over when you ejaculated?
□ No sexual intercourse (not applicable)
□ Almost always or always
□ More than half the time
□ About half the time
□ Less than half the time
□ Almost never or never
2) Over the past 4 weeks, when you had sexual intercourse, how much conﬁdence did you have over when you ejaculated?
□ No sexual intercourse (not applicable)
□ High conﬁdence
□ Moderately high conﬁdence
□ Neither high nor low conﬁdence
□ Moderately low conﬁdence
□ Low conﬁdence
3) Over the past 4 weeks, when you had sexual intercourse, how often was it satisfactory for you?
□ No sexual intercourse (not applicable)
□ Almost always or always
□ More than half the time
□ About half the time
□ Less than half the time
□ Almost never or never
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4) Over the past 4 weeks, when you had sexual intercourse, how satisﬁed were you with your sense of control over when you ejaculated?
□ No sexual intercourse (not applicable)
□ Very satisﬁed
□ Somewhat satisﬁed
□ Neither satisﬁed nor dissatisﬁed
□ Somewhat dissatisﬁed
□ Very dissatisﬁed
5) Over the past 4 weeks, when you had sexual intercourse, how satisﬁed were you with the length of intercourse before
ejaculation?
□ No sexual intercourse (not applicable)
□ Very satisﬁed
□ Somewhat satisﬁed
□ Neither satisﬁed nor dissatisﬁed
□ Somewhat dissatisﬁed
□ Very dissatisﬁed
6) Over the past 4 weeks, how satisﬁed have you been with your sex life overall?
□ No sexual intercourse (not applicable)
□ Very satisﬁed
□ Somewhat satisﬁed
□ Neither satisﬁed nor dissatisﬁed
□ Somewhat dissatisﬁed
□ Very dissatisﬁed
7) Over the past 4 weeks, how satisﬁed have you been with your sexual relationship with your partner?
□ No sexual intercourse (not applicable)
□ Very satisﬁed
□ Somewhat satisﬁed
□ Neither satisﬁed nor dissatisﬁed
□ Somewhat dissatisﬁed
□ Very dissatisﬁed
8) Over the past 4 weeks, how much pleasure has sexual intercourse given you?
□ No sexual intercourse (not applicable)
□ High pleasure
□ Moderate high pleasure
□ Neither high nor low pleasure
□ Moderately low pleasure
□ Low pleasure
9) Over the past 4 weeks, how distressed (frustrated) were you by how long you lasted before you ejaculated?
□ No sexual intercourse (not applicable)
□ Extremely distressed
□ Very distressed
□ Moderately distressed
□ Slightly distressed
□ Not at all distressed
10) Over the past 4 weeks, how distressed (frustrated) have you been about your control over ejaculation?
□ No sexual intercourse (not applicable)
□ Extremely distressed
□ Very distressed
□ Moderately distressed
□ Slightly distressed
□ Not at all distressed
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Premature Ejaculation Profile (PEP Items)
Over the past month, was your control over ejaculation during sexual intercourse:
□ Very poor □ Poor □ Fair □ Good □ Very good
Over the past month, was your satisfaction with sexual intercourse:
□ Very poor □ Poor □ Fair □ Good □ Very good
Over the past month, how distressed were you by how fast you ejaculated during sexual intercourse?
□ Not at all □ A little □ Moderately □ Quite a bit □ Extremely
Over the past month, to what extent did how fast you ejaculated during sexual intercourse cause difficulty in your relationship with your
partner?
□ Not at all □ A little □ Moderately □ Quite a bit □ Extremely
PE Diagnostic Tool (PEDT)
Patient Instructions
This next questionnaire is designed to help identify men who may have a problem with ejaculating too soon during sexual activity. Even
if you do not have difﬁculties, please answer all the questions:
Please mark X in the box that best represented you answer for each of the questions below.
Please mark only one box for each question.
While your experiences may change from time to time, please report your general experiences with intercourse.
Deﬁnition: Ejaculation here refers to ejaculation (release of semen) after penetration (when your penis enters your partner).
Not difficult
at all
Somewhat
difficult
Moderately
difficult
Very
difficult
Extremely
difficult
1) How difficult is it for you to delay
ejaculation?
□ 0 □ 1 □ 2 □ 3 □ 4
Almost never
or never (0%)
Less than half
the time (25%)
About half the
time (50%)
More than half
the time (75%)
Almost always
or always (100%)
2) Do you ejaculate before you wish? □ 0 □ 1 □ 2 □ 3 □ 4
3) Do you ejaculate with very little
stimulation?
□ 0 □ 1 □ 2 □ 3 □ 4
Not at all Slightly Moderately Very Extremely
4) Do you feel frustrated because of
ejaculating before you want to?
□ 0 □ 1 □ 2 □ 3 □ 4
5) How concerned are you that your time
to ejaculation leaves your partner
sexually unfulfilled?
□ 0 □ 1 □ 2 □ 3 □ 4
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